Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

HLA-G expression in non-small cell lung cancer: prognostic significance and interplay with PD-L1 and CD8<sup>+</sup> tumor-infiltrating lymphocytes.

Frontiers in immunology·2026
Same author

Virtual Evaluation of Hematoxylin & Eosin via Digital Pathology Survey (VEED) Project: Results from a Non-Inferiority Study of a Tabs-Based Staining Method.

Diagnostics (Basel, Switzerland)·2026
Same author

Mixed/combined pulmonary non-small cell carcinoma and carcinoid: State-of-the-Art review of clinical, histological, and molecular features with therapeutic implications.

Histology and histopathology·2026
Same author

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Experimental and molecular pathology·2026
Same author

Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables.

Frontiers in pharmacology·2026

Related Experiment Video

Updated: May 24, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1000

Impact and Reproducibility of In-House Targeted Next-Generation Sequencing Biomarker Testing in Non-Small-Cell Lung

Ida Rapa1, Francesca Bertola2, Gaia Roversi3

  • 1Pathology Unit, San Luigi Gonzaga Hospital, Turin, Italy.

The Journal of Molecular Diagnostics : JMD
|March 1, 2025
PubMed
Summary

Implementing in-house next-generation sequencing (NGS) for non-small-cell lung cancer (NSCLC) offers significant benefits. This multi-institutional study confirmed its analytical performance, efficiency, and feasibility for molecular pathology labs.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K

Related Experiment Videos

Last Updated: May 24, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1000
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K

Area of Science:

  • Oncology
  • Molecular Pathology
  • Genomics

Background:

  • Next-generation sequencing (NGS) enables comprehensive genetic profiling in diverse cancer types.
  • Molecular pathology laboratories seek efficient methods for analyzing multiple genetic targets in non-small-cell lung cancer (NSCLC).

Purpose of the Study:

  • To evaluate the analytical performance, turnaround time, and feasibility of implementing in-house NGS testing for NSCLC.
  • To confirm the benefits of in-house NGS for molecular pathology laboratories analyzing NSCLC samples.

Main Methods:

  • A multi-institutional study involving retrospective (n=21) and prospective (n=262) phases.
  • Analysis of 50 genes using NGS on 283 NSCLC samples, assessing DNA and RNA.
  • Evaluation of interlaboratory concordance, variant allele fraction correlation, and turnaround time.

Main Results:

  • High sequencing success rates (99.2% DNA, 98% RNA in prospective phase) and interlaboratory concordance (95.2%).
  • NGS identified 285 relevant variants, including single-nucleotide variants, copy number variants, and gene fusions.
  • Co-mutations were found in 20.5% of main oncogenic driver-positive samples, and 11% of wild-type samples had other relevant alterations.
  • Median turnaround time from sample processing to molecular report was 4 days.

Conclusions:

  • In-house NGS testing demonstrates robust analytical performance and feasibility for NSCLC molecular pathology.
  • The implementation of in-house NGS testing provides significant advantages in terms of efficiency and comprehensive variant detection.
  • This approach facilitates the identification of actionable co-mutations and alterations in NSCLC, supporting personalized treatment strategies.